Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors

NCT ID: NCT05731947

Last Updated: 2026-01-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-04
• Study Completion Date: 2025-06-30

Brief Summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.

Detailed Description

The study will be conducted in two parts. The Phase 1 portion of the study consists of a dose escalation cohort, and a signal-seeking expansion where anti-tumor activity signals will be evaluated. The Phase 2 portion of the study will further confirm the anti-tumor activity signals of revumenib.

Conditions

Colorectal Cancer; Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1a: Dose Escalation

Participants will receive revumenib tablets or capsules three times a day (TID) or two times a day (BID) from Day 1 of each 28-day cycle.

Group Type: EXPERIMENTAL

Revumenib

Intervention Type: DRUG

Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Phase 1b: Signal-Seeking

Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.

Group Type: EXPERIMENTAL

Revumenib

Intervention Type: DRUG

Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Phase 2: Revumenib

Participants will receive revumenib tablets TID or BID from Day 1 of each 28-day cycle.

Group Type: EXPERIMENTAL

Revumenib

Intervention Type: DRUG

Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Phase 2: Chemotherapy

Participants will receive chemotherapy from Day 1 of each 28-day cycle.

Group Type: ACTIVE_COMPARATOR

Chemotherapy

Intervention Type: DRUG

Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Interventions

Revumenib

Revumenib administered orally with or without food. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Intervention Type: DRUG

Chemotherapy

Either Lonsurf® or Stivarga® administered per the investigator's choice at the respective drug label's dose and schedule. Participants may continue to receive treatment until disease progression or until they experience unacceptable toxicity.

Intervention Type: DRUG

Other Intervention Names

SNDX-5613

Eligibility Criteria

Inclusion Criteria

• Male and female participants aged ≥18 years
• Participants with metastatic CRC or other solid tumors
• Evidence of locally recurrent or metastatic disease based on imaging studies within 28 days of cycle 1/day 1 (C1D1)
• CRC participants must have had at least one line of standard-of-care therapy and must have progressed on or been intolerant to, or unable to receive oxaliplatin, irinotecan, and bevacizumab in the advanced/metastatic setting.
• Other solid tumor participants must have had all approved standard therapies that are available to the participant, unless contraindicated or intolerable.
• Participants must have experienced documented unequivocal progressive disease by either RECIST v1.1 or clinical assessment, or experienced unacceptable toxicity with their prior therapy.
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1
• If receiving radiation therapy, has had a 2-week washout period following completion of the treatment prior to receiving the C1D1 dose and continues to have at least 1 measurable lesion
• At least 42 days since prior immunotherapy, including tumor vaccines and checkpoint inhibitors, and at least 21 days since receipt of chimeric antigen receptor therapy or other modified T-cell therapy
• Adequate bone marrow, renal, cardiac, and liver function

Exclusion Criteria

• Participant has a prior history of malignant bowel obstruction requiring hospitalization in the 6 months prior to enrollment
• Participant has a history of uncontrolled ascites, defined as symptomatic ascites and/or repeated paracenteses for symptom control in the past 3 months
• Detectable human immunodeficiency virus (HIV) viral load within the previous 6 months. Participants with a known history of HIV 1/2 antibodies must have viral load testing prior to study enrollment
• Hepatitis B and/or C
• Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure (New York Heart Association Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or transient ischemic attack
• Corrected QT interval (QTc) >450 milliseconds
• Any gastrointestinal (GI) issue of the upper GI tract likely to affect oral drug absorption or ingestion (for example, gastric bypass, gastroparesis)
• Cirrhosis with a Child-Pugh score of B or C
• Brain metastasis except for those participants who have completed definitive therapy, are not on steroids, have a stable neurologic status for at least 4 weeks after completion of the definitive therapy and steroids, and do not have neurologic dysfunction that would confound the evaluation of neurologic and other adverse events (AEs)
• History of or any concurrent condition, therapy, laboratory abnormality, or allergy to excipients that in the Investigator's opinion might confound the results of the study, interfere with the participant's ability to participate for the full duration of the study, or not be in the best interest of the participant to participate
• Participant has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study baseline or who has not recovered (that is, ≤Grade 1 or at baseline) from AEs related to a previously administered agent.
• Participation in another therapeutic interventional clinical study in which an investigational agent was administered within 30 days before starting revumenib
• Participant has received a transfusion of blood products or administration of colony stimulating factors within 4 weeks of the first dose of the study drug
• History of additional malignancy within the prior 5 years, excluding adequately treated basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia/cervical carcinoma in situ, or melanoma in situ or ductal carcinoma in situ of the breast

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Syndax Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Honor Health Research Institute

Scottsdale, Arizona, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Memorial Sloan Kettering Cancer Center

Manhattan, New York, United States

Gabrail Cancer Center

Canton, Ohio, United States

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States

Inova Schar Cancer Institute

Fairfax, Virginia, United States

Countries

United States

Other Identifiers

SNDX-5613-0706

Identifier Type: -

Identifier Source: org_study_id